Latest on Ultrasound Renal Denervation
Published: 22 June 2022
-
Views:
7422 -
Likes:
7
-
Views:
7422 -
Likes:
7
-
5m 10s
-
4m 44s
-
16m 20sPart 5 | Session 3 ACC 2021 – RADIANCE-HTN TRIO Trial Results with Ajay Kirtane
-
5m 47sPart 5 | Session 4 EuroPCR 2020 – Crossover Results From the RADIANCE-HTN SOLO Trial
-
1h 4m 58sPart 7 | Session 1 ACC 2022 Symposium
-
59m 32sPart 7 | Session 2 TCT 2021 Symposium
-
4m 2sPart 1 | Session 1 The Science of Ultrasound Renal Denervation: Introduction Philipp Lurz, Michael Joner, Felix Mahfoud, Andrew Wu
-
9m 18sPart 1 | Session 2 Ultrasound Technology – Its Development and Unique Characteristics: Andy Wu Andrew Wu
-
15m 10sPart 1 | Session 3 Ultrasound Renal Denervation Preclinical Evidence: Dr Michael Joner Michael Joner
-
18m 36sPart 1 | Session 4 RDN Procedure with Ultrasound Technology: Prof Felix Mahfoud Felix Mahfoud
-
10m 14sPart 1 | Session 5 Panel Discussion: All Philipp Lurz, Michael Joner, Felix Mahfoud, Andrew Wu
-
15m 15sPart 2 | Session 1 The Paradise uRDN System: Dr Andrew Sharp Andrew SP Sharp
-
9m 57sPart 2 | Session 2 uRDN Clinical Evidence - What does this mean for the field?: Prof Felix Mahfoud Felix Mahfoud
-
21m 53sPart 2 | Session 3 How to build uRDN centre / therapy pathway: Prof Roland Schmieder Roland E Schmieder
-
19m 35sPart 3 | Session 1 Introduction and "Ultrasound RDN - Reviewing the Latest Clinical Results" : Atul Pathak Joost Daemen, Atul Pathak, Joachim Weil
-
11m 41sPart 3 | Session 2 "Ultrasound RDN - Reviewing the Latest Clinical Results" : Joost Daemen Joost Daemen, Atul Pathak, Joachim Weil
-
28m 37sPart 3 | Session 3 "How to build Interventional HTN Therapy/Practice": Joachim Weil Joost Daemen, Atul Pathak, Joachim Weil
-
5m 12sPart 4 | Session 1 RADIANCE II Pivotal Trial Ajay J Kirtane
Overview
Ultrasound Renal Denervation (uRDN) is an innovative therapy option for the treatment of uncontrolled hypertension. uRDN therapy is delivered in a minimally invasive procedure that may lower high blood pressure by treating overactive renal nerves with ultrasound energy.
This page provides an overview of uRDN technology and the latest evidence from its associated RADIANCE clinical program.
The PARADISETM System is Limited to Investigational Use Only in the United States. Approved for distribution in CE mark countries only.
This educational content is supported by:
What you will learn:
- How uRDN works and its potential benefits for patients suffering from uncontrolled hypertension
- The clinical evidence supporting uRDN and its implications for the field of hypertension
- The process for building a uRDN centre and therapy network
This page is designed for:
- Interventional cardiologists
- General cardiologists
- Hypertension specialists
- Nephrologists
- Interventional radiologists
More from this programme
Part 1
The Science of uRDN
Understand the science of Ultrasound Renal Denervation (uRDN) and its potential benefits for the treatment of uncontrolled hypertension
Part 2
The Evidence for uRDN
Part 3
From Proof to Practice – Treating Hypertension With uRDN
Part 4
RADIANCE II Pivotal Trial for Paradise Ultrasound Renal Denervation System in Patients With Hypertension
TCT 2022 Satellite Symposium.
Part 5
Results From the Latest Clinical Trials
Deep dive into the latest information on the RADIANCE-HTN trials
Part 6
Patient Perspective & Provider Referral Development
Understand patient preference and referral development
Part 7
Discussion With Experts
2 sessions | |
ACC 2022 Symposium | Watch now |
TCT 2021 Symposium | Watch now |